PT  - JOURNAL ARTICLE
AU  - Das, Ashis Kumar
AU  - Mishra, Shiba
AU  - Gopalan, Saji Saraswathy
TI  - Predicting CoVID-19 community mortality risk using machine learning and development of an online prognostic tool
AID  - 10.1101/2020.04.27.20081794
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.27.20081794
4099  - http://medrxiv.org/content/early/2020/05/13/2020.04.27.20081794.short
4100  - http://medrxiv.org/content/early/2020/05/13/2020.04.27.20081794.full
AB  - Background The recent pandemic of CoVID-19 has emerged as a threat to global health security. There are a very few prognostic models on CoVID-19 using machine learning.Objectives To predict mortality among confirmed CoVID-19 patients in South Korea using machine learning and deploy the best performing algorithm as an open-source online prediction tool for decision-making.Materials and methods Mortality for confirmed CoVID-19 patients (n=3,299) between January 20, 2020 and April 30, 2020 was predicted using five machine learning algorithms (logistic regression, support vector machine, K nearest neighbor, random forest and gradient boosting). Performance of the algorithms was compared, and the best performing algorithm was deployed as an online prediction tool.Results The random forest algorithm was the best performer in terms of predictive ability (accuracy=0.981), discrimination (area under ROC curve=0.886), calibration (Matthews Correlation Coefficient=0.459; Brier Score=0.063) and. The best performer algorithm (random forest) was deployed as the online CoVID-19 Community Mortality Risk Prediction tool named CoCoMoRP (https://ashis-das.shinyapps.io/CoCoMoRP/).Conclusions We describe the development and deployment of an open-source machine learning tool to predict mortality risk among CoVID-19 confirmed patients using publicly available surveillance data. This tool can be utilized by potential stakeholders such as health providers and policy makers to triage patients at the community level in addition to other approaches.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are publicly available from Korea CDC